FN-1501
- Generic Name
- FN-1501
- Brand Names
- Cellcept, Myfenax, CellCept, Mycophenolate mofetil Teva, Myclausen
- Drug Type
- Small Molecule
- Chemical Formula
- C22H25N9O
- CAS Number
- 1429515-59-2
- Unique Ingredient Identifier
- 6MC966B505
- Background
Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as Cyclosporine and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants. It is markete...
- Indication
Mycophenolate mofetil is indicated in combination with other immunosuppressants to prevent the rejection of kidney, heart, or liver transplants in adult and pediatric patients ≥3 months old. Mycophenolate mofetil may also be used off-label as a second-line treatment for autoimmune hepatitis that has not responded adequately to first-line therapy. Other off-l...
- Associated Conditions
- Transplanted Organ Rejection
- Associated Therapies
- -
Concentration Controlled Versus Fixed Dose of MMF in Kidney Transplant Recipients
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2008-12-16
- Lead Sponsor
- University Hospital, Limoges
- Target Recruit Count
- 137
- Registration Number
- NCT00199667
- Locations
- 🇫🇷
Néphrologie, Tours, France
Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis.
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2011-10-14
- Lead Sponsor
- Frédéric A. Houssiau, MD, PhD
- Target Recruit Count
- 105
- Registration Number
- NCT00204022
- Locations
- 🇧🇪
Université catholique de Louvain, Bruxelles, Belgium
Pilot Study of Mycophenolate Mofetil in Congenital Uropathies
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-10-19
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 12
- Registration Number
- NCT00193635
- Locations
- 🇺🇸
Robert Wood Johnson Medical center, New Brunswick, New Jersey, United States
🇺🇸Cornell Weill Medical Center, New York, New York, United States
🇺🇸Schneider Children's Hospital, New Hyde Park, New York, United States
Study Evaluating Sirolimus in Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-04-28
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 61
- Registration Number
- NCT00195273
MPA PK Monitoring Strategy With MMF/FK Based Immunosuppression
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2012-06-20
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 22
- Registration Number
- NCT00187941
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
Pharmacokinetics of Mmf and Valganciclovir
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2016-05-25
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 16
- Registration Number
- NCT00189150
- Locations
- 🇺🇸
University of Michigan Hospital, Ann Arbor, Michigan, United States
Allogeneic Transplantation From Related Haploidentical Donors
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2019-12-04
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 16
- Registration Number
- NCT00185692
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2012-10-02
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 9
- Registration Number
- NCT00183248
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Stem Cell Transplant for Immunologic or Histiocytic Disorders
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 19
- Registration Number
- NCT00176865
- Locations
- 🇺🇸
Masonic Cancer Center University of Minnesota, Minneapolis, Minnesota, United States
Fixed Dose MMF vs Concentration Controlled MMF After Renal Transplantation
- Conditions
- Interventions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2009-02-12
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 901
- Registration Number
- NCT00166244
- Locations
- 🇧🇪
University Hospitals Leuven, Leuven, Belgium
🇨🇦Vancouver General Hospital, Vancouver, British Columbia, Canada
🇦🇺Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.